EGFR and non-small cell lung carcinoma: This study will investigate the efficacy and safety of continuous EGFR‐TKI and apatinib (angiogenesis inhibitor) treatment in patients with NSCLC determined to have slow progression by CEA or imaging after first‐line treatment with EGFR‐TKI (including erlotinib, gefitinib, and icotinib).